Adverum Biotechnologies, Inc. | Business Contracts

Amended and Restated (Filed With SEC on August 11, 2022)

Consulting Agreement between Adverum Biotechnologies, Inc. and Nancy E. Pecota, dated as of June 29, 2022 (Filed With SEC on August 11, 2022)

Sublease Agreement between Adverum NC, LLC and Jaguar Gene Therapy, LLC, dated as of October 26, 2021 (Filed With SEC on March 29, 2022)

Description of Common Stock (Filed With SEC on March 1, 2021)

Form of Indemnification Agreement for Directors and Executive Officers (Filed With SEC on May 28, 2020)

License Agreement, between the Company and Virovek, Inc. (Virovek), dated October 12, 2011 (the Virovek License) (Filed With SEC on March 6, 2019)

Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of June 7, 2022 (Filed With SEC on August 11, 2022)

Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of June 4, 2022 (Filed With SEC on August 11, 2022)

Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of July 1 (Filed With SEC on August 11, 2022)

Employment Agreement between Adverum Biotechnologies, Inc. and John Rakow, dated as of January 2 (Filed With SEC on August 11, 2022)

Employment Agreement (Filed With SEC on March 29, 2022)

Employment Agreement between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of November 12, 2021 (Filed With SEC on March 29, 2022)

Employment Agreement between Adverum Biotechnologies, Inc. and Brigit Riley, dated as of May 21, 2021 (Filed With SEC on March 29, 2022)

Form of Change in Control (Filed With SEC on March 29, 2022)

Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2014 Equity Incentive Award Plan (Filed With SEC on March 29, 2022)

Sublease Agreement between Adverum Biotechnologies, Inc. and Revolution Medicines, Inc., dated as of November 1, 2021 (Filed With SEC on March 29, 2022)

Second Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of November 1, 2021 (Filed With SEC on March 29, 2022)

Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Angela Thedinga, dated October 1, 2021 (Filed With SEC on November 4, 2021)

Consulting Agreement between Adverum Biotechnologies, Inc. and Angela Thedinga, dated October 1, 2021 (Filed With SEC on November 4, 2021)

Change in Control and Severance Agreement with Chris DeRespino, dated February 1, 2021 (Filed With SEC on August 5, 2021)

Employment Offer Letter with Chris DeRespino, dated February 1, 2021 (Filed With SEC on August 5, 2021)

Change in Control and Severance Agreement with Julie Clark, dated May 25, 2021 (Filed With SEC on August 5, 2021)

Promotion Letter with Julie Clark, dated May 22, 2021 (Filed With SEC on August 5, 2021)

Employment Offer Letter with Julie Clark, dated April 2, 2020 (Filed With SEC on August 5, 2021)

Consulting Agreement between Adverum Biotechnologies, Inc. and Leone Patterson, dated June 24, 2021 (Filed With SEC on August 5, 2021)

First Lease Amendment by and between HCP LS Redwood City, LLC and Adverum Biotechnologies, Inc., dated (Filed With SEC on August 5, 2021)

Non-Employee Director Compensation Policy, effective May 5, 2021 (Filed With SEC on May 6, 2021)

Non-Employee Director Compensation Policy, effective March 31, 2021 (Filed With SEC on May 6, 2021)

Lease Agreement and Letter Agreement by and between Adverum NC, LLC (a wholly owned subsidiary of Adverum Biotechnologies, Inc.) and ARE-NC REGION NO. 21, LLC, dated January 8,... (Filed With SEC on May 6, 2021)

Consulting Agreement between Adverum Biotechnologies, Inc. and Thomas Leung, dated February 2, 2021 (Filed With SEC on May 6, 2021)

Separation Agreement between Adverum Biotechnologies, Inc. and Thomas Leung, dated February 2, 2021 (Filed With SEC on May 6, 2021)

Consulting Agreement between Adverum Biotechnologies, Inc. and Aaron Osborne, dated March 18, 2021 (Filed With SEC on May 6, 2021)

Separation Agreement between Adverum Biotechnologies, Inc. and Aaron Osborne, dated April 7, 2021 (Filed With SEC on May 6, 2021)

Common Stock Sales Agreement, dated December 17, 2020 (Filed With SEC on December 17, 2020)

Underwriting Agreement, dated August 12, 2020 (Filed With SEC on August 13, 2020)

Adverum Biotechnologies, Inc. Amended and Restated 2017 Inducement Plan (Filed With SEC on August 10, 2020)

Adverum Biotechnologies, Inc. Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on August 10, 2020)

Adverum Biotechnologies, Inc. Amended and Restated 2006 Equity Incentive Plan (Filed With SEC on August 10, 2020)

Amended and Restated Non-Employee Director Compensation Policy, effective June 22, 2020 (Filed With SEC on August 10, 2020)

Amended and Restated Change in Control and Severance Agreement with Leone Patterson, dated (Filed With SEC on August 10, 2020)

Amended and Restated Offer Letter with Leone Patterson, dated (Filed With SEC on August 10, 2020)

Change in Control and Severance Agreement Laurent Fischer, dated (Filed With SEC on August 10, 2020)

Employment Offer Letter with Laurent Fischer, dated (Filed With SEC on August 10, 2020)

Promotion Letter, dated February 21, 2020, between Adverum Biotechnologies, Inc. and Angela Thedinga (Filed With SEC on May 28, 2020)

Employment Agreement, dated (Filed With SEC on May 28, 2020)

Description of Common Stock (Filed With SEC on March 12, 2020)

Non-Employee Director Compensation Policy, effective December 13, 2019 (Filed With SEC on March 12, 2020)

Underwriting Agreement, dated February 11, 2020 (Filed With SEC on February 12, 2020)

Non-Employee Director Compensation Policy, effective August 15, 2019 (Filed With SEC on November 7, 2019)

Separation Letter and Consulting Agreement, dated September 3, 2019 and September 6, 2019, respectively, between Adverum Biotechnologies, Inc. and Jennifer Cheng (Filed With SEC on November 7, 2019)

Separation and Consulting Agreement, dated July 31, 2019, between Adverum Biotechnologies, Inc. and Mehdi Gasmi (Filed With SEC on November 7, 2019)

Employment Agreement, dated October 11, 2019, among Adverum Biotechnologies, Inc. and Peter Soparkar (Filed With SEC on November 7, 2019)

Employment Agreement, dated February 28, 2019, among Adverum Biotechnologies, Inc. and Aaron Osborne (Filed With SEC on November 7, 2019)

Separation Letter, dated May 1, 2019, between Adverum Biotechnologies, Inc. and Paul Cleveland (Filed With SEC on August 8, 2019)

Employment Agreement, dated February 27, 2019, with Thomas Leung (Filed With SEC on May 8, 2019)

Cooperation Agreement, dated as of May 1, 2019, among Adverum Biotechnologies, Inc., The Sonic Fund II, L.P. and Lawrence Kam (Filed With SEC on May 2, 2019)

2017 Inducement Plan, as amended and restated (Filed With SEC on March 6, 2019)

Exclusive License Agreement, between the Company and the Regents of the University of California (UC), dated June 17, 2013 (the UC License) (Filed With SEC on March 6, 2019)

Amendment to the Change in Control and Severance Agreement for Mehdi Gasmi (Filed With SEC on March 6, 2019)

Amended and Restated Offer Letter with Leone Patterson, dated October 24, 2018 (Filed With SEC on March 6, 2019)

Change in Control and Severance Agreement with Leone Patterson, dated October 24, 2018 (Filed With SEC on March 6, 2019)

Adverum Biotechnologies, Inc. 2014 Equity Incentive Award Plan, as amended and restated (Filed With SEC on March 6, 2019)

Adverum Biotechnologies, Inc. 2014 Employee Stock Purchase Plan, as amended and restated (Filed With SEC on March 6, 2019)

Adverum Biotechnologies, Inc. (65)